Vocal Characteristics of Children With Short Stature Before and After Growth Hormone Treatment.

Plain-language guide to PMID 35090764 (2024): observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 23 children.

Key Facts

PMID: 35090764
Journal: Journal of voice : official journal of the Voice Foundation
Year: 2024
Study type: Observational Study
Authors: Xavier CB et al. (5 authors)
DOI: 10.1016/j.jvoice.2022.01.004

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this observational study publication.

To evaluate the vocal characteristics of children with short stature before and 12 months after growth hormone treatment.

Who Took Part

The abstract describes 23 children taking part.

The age groups tagged for this paper are young children and children, both men and women.

This analytical, observational cohort study included 23 children (age 5-11 years) diagnosed with short stature.

Children in the short stature group (SSG) were matched (1:1) for age and sex with children with normal growth (normal stature group; NSG).

How the Study Was Run

Participants in the SSG underwent assessments before and 12 months after growth hormone treatment, while those in the NSG underwent the same assessments at baseline and 12 months.

The assessments included evaluation of (A) vocal characteristics (history, vocal self-assessment, auditory-perceptual evaluation, and acoustic analysis), (B) anthropometry, (C) bone age, and (D) measurement of insulin-like growth factor-1 (IGF-1) levels.

What Was Measured

Topics PubMed links to this paper include Voice Quality, Human Growth Hormone, Insulin-Like Growth Factor I, Speech Acoustics, Body Height, Speech Production Measurement and Voice Disorders.

Author keywords: Short stature.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 23 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Journal of voice : official journal of the Voice Foundation), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.